SCHEMBL22499185

SCHEMBL22499185

O=C(CCc1ccccc1)Oc1c(F)c(F)c(F)c(F)c1F

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.58
KMT2A Q03164 2/20 0.56
TSHR P16473 1/20 0.53
ALDH1A1 P00352 2/20 0.52
KEAP1 Q14145 1/20 0.50
FFAR1 O14842 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
AKR1C3 P42330 1/20 0.45
MAPT P10636 2/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
KDM4E B2RXH2 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TRPV1 Q8NER1 1/20 0.43
ALOX5 P09917 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22528727 0.89 TDP1 (0.53) TDP1KMT2ATSHRALDH1A1KEAP1
SCHEMBL6937307 0.82 SMN1; SMN2 (0.67) KMT2ATSHRALDH1A1SMN1; SMN2MAPT
SCHEMBL11527185 0.81 SMN1; SMN2 (0.71) TDP1KMT2AALDH1A1KEAP1FFAR1
SCHEMBL20673370 0.80 ALDH1A1 (0.50) TDP1KMT2ATSHRALDH1A1SMN1; SMN2
SCHEMBL16217874 0.80 ALDH1A1 (0.50) TDP1KMT2ATSHRALDH1A1SMN1; SMN2
SCHEMBL20869833 0.80 SMN1; SMN2 (0.48) TDP1KMT2ATSHRALDH1A1SMN1; SMN2
SCHEMBL28439801 0.79 AKR1C3 (0.54) TDP1KMT2AALDH1A1NPC1RAB9A
SCHEMBL26315892 0.79 ALDH1A1 (0.49) TDP1KMT2AALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL27740914 0.79 TDP1 (0.42) TDP1KMT2ATSHRALDH1A1SMN1; SMN2
SCHEMBL9848619 0.79 KMT2A (0.43) KMT2AALDH1A1MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388577-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LTD (GB) 2025-12-25 US disclosed
US-12358915-B2 METTL3 inhibitory compounds STORM Therapeutics Ltd. (GB) 2025-07-15 US disclosed
US-20230085408-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LIMITED (GB) 2023-03-16 US disclosed
EP-3946618-A1 METTL3 INHIBITORY COMPOUNDS Storm Therapeutics Ltd (GB) 2022-02-09 EP disclosed
CN-113905787-A METTL3 inhibiting compounds 斯托姆治疗有限公司 2022-01-07 CN disclosed
WO-2020201773-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LTD (GB) 2020-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12358915-B2 METTL3 inhibitory compounds METTL3, METTL16, DIMT1 TDP1 1209/4885KMT2A 110/4885TSHR 3169/4885
US-20250388577-A1 METTL3 INHIBITORY COMPOUNDS METTL3, RNMT, TPMT TDP1 725/4885KMT2A 534/4885TSHR 342/4885
US-20230085408-A1 METTL3 INHIBITORY COMPOUNDS METTL3, METTL16, DIMT1 TDP1 1209/4885KMT2A 110/4885TSHR 3169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.